Clinical Biochemistry Publishes Paper About Cruelty-Free Insulin Assay
A scientific paper about PCRM’s groundbreaking development of the world’s first cruelty-free insulin assay was published in the January issue of the Canadian Society of Clinical Chemists’ prestigious journal, Clinical Biochemistry. The journal is read by chemists, biochemists, immunologists, biologists, and other scientists and researchers around the world. The paper will serve to promote the use of PCRM’s assay and encourage researchers to develop alternatives to other tests that use animal-derived ingredients.
Authored by PCRM toxicology and research consultant Megha Even, M.S., director of toxicology and research Chad Sandusky, Ph.D., and president Neal Barnard, M.D., the paper describes how the assay was developed without the use of animals. Insulin assays, which are used to analyze the insulin levels in the blood of people with diabetes, have traditionally involved the use of painful in vivo procedures, such as growing antibodies in the abdomen of mice, and the use of fetal-calf serum, a cruel slaughterhouse byproduct that can harbor viruses and other infectious agents. But PCRM’s reliable and precise assay offers a humane alternative that is as good as—if not better than—standard assays.
PCRM decided to develop its own assay when Dr. Barnard launched an important clinical trial to test the effect of a low-fat vegan diet on patients with type 2 diabetes in 2004. At that time, the laboratories he contracted with for clinical tests measured insulin by using antibodies from mice and fetal-calf serum. So PCRM began work with researchers at Linco Research of St. Charles, Mo., to develop a cruelty-free insulin assay.
PCRM’s insulin assay is now marketed by Millipore (formerly Linco Research) as the company’s preferred insulin assay. Millipore has sold enough kits to run almost 10,000 insulin tests, and researchers are so pleased with the accurate results that PCRM’s cruelty-free assay has replaced the conventional kit sold by the company.